Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

NCT05833022 · clinicaltrials.gov ↗
COMPLETED
Status
297
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Novartis Pharmaceuticals